AzTrials
AzTrials

Lung CancerVALIDIAGNCT06007261

Validation of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope

An observational study of Lung Cancer, run by Radboud University Medical Center at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to verify a new microscopic technique in diagnosing patients suspected of lung cancer. Patients will undergo navigational bronchoscopy or surgical resection as a part of standard of care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lung Cancer
How many people
250 participants
Where
1 siteNetherlands
Study dates
19 Jan 2024to Apr 2027
How long will I take part?
20 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population will consist of patients with a pulmonary lesion(s) with an indication for surgical resection according to guideline recommended care, multi-discplinary tumor board decision making and patient preferences. Median age will be approximately 65 years. Sex distribution will be approximately 50-60% male, 40-50% female based on prior studies at the Radboudumc.

Who may be able to join

  • ASA physical status 1-3.
  • Age 18 years or older.
  • A pulmonary lesion with an indication for diagnostic or therapeutic evaluation following current clinical guidelines and/or as decided by multi-disciplinary team consultation.

Who cannot join

  • Bleeding disorders.
  • Less than 18 years old.
  • Inability to consent.
  • Unfit for navigation bronchoscopy and/or unfit for surgical resection as per guideline recommended care and multi-disciplinary tumor board decision making.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Roel LJ Verhoeven, PhD contact

0031627495531

roel.lj.verhoeven@radboudumc.nl

Judith JM Leermakers-Ceelen, PhD contact

0031631117495

Judith.Leermakers-Ceelen@radboudumc.nl

Netherlands1 site, 1 recruiting
  • Radboudumc

    Nijmegen, Gelderland, 6525GA

    Roel LJ Verhoeven, PhD, 0031627495531, roel.lj.verhoeven@radboudumc.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Validation and Added Clinical Value of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope

The aim of this study is to verify a new microscopic technique in diagnosing patients suspected of lung cancer. Patients will undergo navigational bronchoscopy or surgical resection as a part of standard of care. Biopsies taken during this procedure will be imaged for a few minutes with a higher harmonic generation (HHG) microscope, after which the material is taken to the pathology department for histopathology assessment, which is currently the golden standard for diagnosis.

Read the detailed description

The gold standard for diagnosing all suspected malignancies, such as lung cancer, involves pathological examination using light microscopy, supplemented with immunohistochemical techniques and molecular (tissue) diagnostics. The official assessment of this tissue typically occurs after the procedure in which the tissue was obtained, through histological analysis (tissue analysis) or cytological analysis (cell analysis obtained through aspiration). Only then can certainty be provided regarding whether the obtained tissue is qualitatively adequate and/or quantitatively sufficient to make a diagnosis.

To ensure that complex and/or invasive procedures are performed with the correct outcome measures, intraoperative tissue diagnostics would be beneficial. In addition to postoperative assessment, additional intra-procedural evaluation of material for qualitative and quantitative estimation ('rapid onsite evaluation' (ROSE) and 'frozen section examination') is often used for complex and/or invasive procedures. Rapid on-site evaluation of cytopathology is always present during navigational bronchoscopy procedures, while frozen section examination is used for surgical tissue resection (such as in lung cancer surgery, as well as in oncological ENT and oesophageal surgery, among other organ and malignancy suspicions).

Navigational Bronchoscopy For patients with (a suspicion of) early-stage lung cancer, navigational bronchoscopy is a labour-intensive, complex procedure that has now become the new standard of care for diagnosing abnormalities suspicious for lung cancer. An endoscope and a subsequent navigable catheter are used to navigate through the natural airways to the suspicious lesion and obtain a biopsy to make a diagnosis. Since these are often peripheral small lesions, it is crucial to obtain tissue with millimetre precision. During navigational bronchoscopy, the previously mentioned ROSE technique is routinely used to receive feedback during the procedure on whether the obtained tissue is suitable for making a diagnosis. Histological and/or cytological tissue is collected using small instruments during navigational bronchoscopy, such as a slide filled with cell material. The cytology analyst assesses within minutes whether the material is representative by colouring and examining it under the microscope. Representativity means that the material contains enough for performing final pathology diagnostics to explain the abnormality. Since navigational bronchoscopy involves only small biopsies and tissue from the tumour itself or surrounding tissue is not obtained with certainty under direct visualization (biopsies are taken under the guidance of X-ray fluoroscopy), multiple and extensive biopsies are performed. In current clinical practice, routinely more than ten biopsies are taken per patient. In practice, we observe under intraoperative imaging that we could accurately reach the lesion in more than 90% of cases. In later follow-up, it turns out that in about 10-15% of procedures, we still cannot provide a correct diagnosis after analysing the obtained material.

Surgery Similar to ROSE during navigational bronchoscopy, frozen section examination is also requested during surgical procedures when there is no diagnosis available at the start of the procedure or when clinically relevant lymph node stations affect the intervention. Tissue is taken, and an employee brings it to the pathology department. The progress of the surgical procedure is paused. The tissue is frozen on the pathology department to cut sections, which are then coloured and assessed by the pathologist. Due to these activities, this means that the surgeon typically waits for more than half an hour for a pathology result during the surgery.

This approach is customary in numerous surgical procedures, not only in lung surgery but also in procedures for patients with oesophageal cancer, head and neck cancer, and other solid tumours elsewhere in the body.

In many clinical situations, faster and more detailed pathological feedback available during a procedure, providing immediate insights into the origin of abnormalities, could significantly improve clinical practice. Procedure wait times can be shortened, bridging the gap between accurately reaching a lesion and obtaining a diagnosis. It enables a more effective determination of the number of biopsies needed during diagnostic procedures such as navigational bronchoscopy and allows for more accurate intraoperative assessment of whether further therapy is necessary.

Higher Harmonic Generation Microscopy Higher Harmonic Generation Microscopy (HHGM) is a novel digital imaging technique that can generate (digital) microscopy images using laser light during a procedure. This technique produces non-invasive, label-free digital images of living tissue with sub-cellular resolution. The contrast in the images is caused by discontinuities, non-centrosymmetric molecular structures, or auto fluorescent organelles, generating higher optical harmonics and auto fluorescent photons, which are detected with a microscope. HHGM has been previously applied to image various tissue types, such as the breast, brain, and lungs. An earlier study demonstrated that HHGM provides high-quality images of lung tumours within minutes without fixation and staining. The resulting images revealed cell density, cellular and nuclear morphological features of the tumour, as well as extracellular matrix components (fibroblasts, collagen, and elastin), immune cells, red blood cells, and blood vessels. In a subsequent study at Amsterdam UMC, 109 biopsies from 47 patients were imaged within a median of 6 minutes (IQR = 3 minutes) after excision. The image quality was sufficient for diagnosing malignancy or non-malignancy in 97% of the biopsies, and 87% of the HHG images were correctly scored by pathologists.

Importantly, it was demonstrated that this optical imaging had no impact on the standard pathological processing and evaluation. The imaged tissue could be processed and assessed according to normal routine immediately after obtaining the images. In a previous study on human lung tissue at Amsterdam UMC (47 patients), histopathology images taken after imaging with the HHG microscope were evaluated by a pathologist. It was found that imaging with the HHG microscope also had no effect on the tissue or its accessibility. The laser power on the sample is 5 mW, equivalent to the power of a laser pointer.

The obtained tissues, before further processing in accordance with routine clinical processes, are placed in a special container for HHGM imaging. Both the small biopsies obtained, for example, during navigational bronchoscopy, and larger surgical resection tissues requiring longer scanning times are placed in these special containers, minimally moistened by adding a small amount of physiological saline (a drop to several drops) during imaging. This is done to improve imaging and prevent potential dehydration. This addition of physiological saline has no negative effect on the later assessment possibilities of the tissue by the pathologist.

The research protocol described here aims to collect a large number of HHGM images during routine procedures in daily clinical practice, creating a more extensive library of images for understanding HHGM images, training pathologists, and developing an AI algorithm for future computer-assisted diagnostics and/or automatic on-site diagnostics. The images collected during the procedure will not be used for clinical decision-making.

Conditions
Lung Cancer
Keywords
Navigation Bronchoscopy, Higher harmonic generation microscopy, Artificial intelligence, Diagnostics, Surgical resection
Medical subject headings
Lung Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The ability to obtain a diagnosis from HHG microscopy images as judged by the pathologist

    Accuracy of HHG microscopy obtained and assessed images for diagnosing pathology as compared against golden standard routine clinical follow up pathology tissue evaluation techniques (H\&E staining and if used, additional stains), as judged by the pathologist.

    Measured: 48 months

  2. The ability to obtain a diagnosis from HHG microscopy images as autonomously assessed by a developed AI algorithm.

    Accuracy of HHG microscopy image based AI algorithm for autonomous diagnosis of pathology as compared against diagnosis of conventional golden standard routine clinical follow up pathology tissue evaluation techniques (H\&E staining and if used, additional stains).

    Measured: 48 months

Secondary outcomes (1)
  1. The ability to obtain a diagnosis from HHG microscopy images as judged during the procedure (rapid on-site) by the cyto-technician or pathologist.

    • Accuracy of Rapid-On site Assessment (ROSE) of HHG microscopy obtained images when compared against golden standard routinely used ROSE technique in navigation bronchoscopy
    • Accuracy of Rapid-On site Assessment (ROSE) of HHG microscopy obtained images when compared against golden standard routinely used frozen section assessment in cardiothoracic surgery.

    Measured: 48 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2023
  2. Study start19 Jan 2024
  3. Primary completionApr 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
250 participants (estimated)
Target duration
20 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06007261
Sponsor's protocol ID
IMAGIO-VALIDIAG
Acronym
VALIDIAG
Status last verified
Jan 2024
First submitted
18 Jul 2023
Last updated
24 Jan 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Lung Cancer, run by Radboud University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Roel LJ Verhoeven, PhD (0031627495531, roel.lj.verhoeven@radboudumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The ability to obtain a diagnosis from HHG microscopy images as judged by the pathologist (time frame: 48 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in